These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9056583)

  • 1. A comment on so-called individual criteria of bioequivalence.
    Wellek S
    J Biopharm Stat; 1997 Mar; 7(1):17-21. PubMed ID: 9056583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two one-sided tests procedure for assessment of individual bioequivalence.
    Liu J; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):49-61. PubMed ID: 9056588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
    Esinhart JD; Chinchilli VM
    J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual bioequivalence--a European perspective.
    Steinijans VW; Hauschke D
    J Biopharm Stat; 1997 Mar; 7(1):31-4. PubMed ID: 9056585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discussion of individual bioequivalence by M.-L. Chen.
    Gould AL
    J Biopharm Stat; 1997 Mar; 7(1):23-9. PubMed ID: 9056584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Review and use of decision rules for bioequivalence trials].
    Nicolas P; Tod M; Petitjean O
    Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some issues for the consideration of individual bioequivalence.
    Endrenyi L
    J Biopharm Stat; 1997 Mar; 7(1):35-9. PubMed ID: 9056586
    [No Abstract]   [Full Text] [Related]  

  • 13. A log-normal model for individual bioequivalence.
    Phillips KF
    J Biopharm Stat; 1993 Sep; 3(2):185-201. PubMed ID: 8220403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consideration of individual bioequivalence.
    Anderson S; Hauck WW
    J Pharmacokinet Biopharm; 1990 Jun; 18(3):259-73. PubMed ID: 2380920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A three-step procedure for assessing bioequivalence in the general mixed model framework.
    Vuorinen J; Turunen J
    Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.